EUROAPI Innovates Leadership for Future Growth
In a significant shift, EUROAPI has embraced a new phase, marking an evolution in its governance and leadership structure. This transition follows the successful establishment and funding of the FOCUS-27 strategic plan, paving the way for the company to enhance value for its stakeholders.
New Appointments to the Board
The recent developments saw the resignation of Viviane Monges from her roles as Director and Chair of the Board, along with Ludwig de Mot as Chief Executive Officer. In light of this transition, the Board has appointed Emmanuel Blin as the Independent Chair and David Seignolle as the new Chief Executive Officer. These changes take effect immediately, demonstrating the Board's commitment to effective governance.
Leadership Transition Overview
As part of the governance modifications, Elizabeth Bastoni has stepped down from her position as Independent Lead Director but will retain her role as Chair of the Nominations and Compensation Committee. This restructuring is anticipated to provide a fresh perspective and direction moving forward.
Expert Profiles of New Leaders
Emmanuel Blin brings a wealth of knowledge to EUROAPI, having been part of the Board since May 2022. With his background as a former executive at Bristol Myers Squibb, he stands ready to guide the company towards its strategic goals. His extensive experience in the pharmaceutical sector offers valuable insight and strategic direction essential for EUROAPI's future endeavors.
In his statement, Blin expressed enthusiasm for his new role, emphasizing the importance of collaboration within the Board and management team to drive transformation and foster growth for the company. He paid tribute to Monges for her contributions during her tenure, signifying the company's commitment to continuity amidst change.
David Seignolle Steps Up as CEO
David Seignolle, previously serving as Chief Operating Officer and a member of the Executive Committee since October 2023, is set to lead the company as the new CEO. His vast experience in the active pharmaceutical ingredient industry makes him a fitting candidate to oversee EUROAPI's strategic vision and operational execution.
David's Industry Expertise
Before joining EUROAPI, David's career included significant positions at TEVA Pharmaceuticals where he oversaw operations in multiple countries. His previous roles encompassed strategic oversight of API operations and global supply chains. With a proven track record in the industry, David is expected to strengthen the foundations for EUROAPI's future growth.
2024 Outlook Maintained
The management's focus remains unwavering, with EUROAPI maintaining its guidance for the full year 2024. The company anticipates a year-on-year decrease in net sales between 8% to 11%, while forecasting a Core EBITDA margin in the range of 4% to 7%. These projections underline the company’s resilience and strategic planning as it navigates the current economic landscape.
About EUROAPI
EUROAPI is dedicated to innovating and providing active ingredient solutions that meet the evolving needs of customers and patients globally. With a rich portfolio of approximately 200 products, the company excels in utilizing a diverse array of technologies while consistently developing innovative molecules through its CDMO activities.
With a passionate workforce of 3,650, EUROAPI is committed to enhancing access to critical therapies. The company boasts robust research and development capabilities along with six European manufacturing sites ensuring high-quality API production for clients in over 80 countries.
Frequently Asked Questions
What led to the change in leadership at EUROAPI?
The transition in leadership was prompted by the resignation of Viviane Monges as Chair and of Ludwig de Mot as CEO, allowing for a fresh governance approach through new appointments.
Who are the new leaders of EUROAPI?
Emmanuel Blin has been appointed as Independent Chair of the Board, and David Seignolle has taken on the role of Chief Executive Officer.
What is the focus for EUROAPI in 2024?
EUROAPI aims to maintain its guidance for 2024, expecting a sales decrease but also indicating a commitment to enhancing value for its stakeholders.
How experienced are the new leaders?
Emmanuel Blin and David Seignolle bring extensive experience in the pharmaceutical sector, vital for steering EUROAPI’s strategic goals and operational success.
What initiatives does EUROAPI undertake?
EUROAPI focuses on reinventing active ingredient solutions and enhancing access to essential therapies through its diverse product offerings and CDMO activities.
